Preterm birth and the availability of cord blood for HPC transplantation.

PubWeight™: 1.47‹?› | Rank: Top 5%

🔗 View Article (PMID 10924609)

Published in Transfusion on July 01, 2000

Authors

D V Surbek1, W Holzgreve, C Steinmann, S Hahn, A Gratwohl, A Wodnar-Filipowicz, A Tichelli

Author Affiliations

1: Departments of Obstetrics and Gynecology, Medicine (Hematology), and Research (Experimental Hematology) and the Central Laboratories, University Hospital, University of Basel, Switzerland. surbek@hotmail.com

Articles by these authors

Five intermediate complexes in transcription initiation by RNA polymerase II. Cell (1989) 9.22

Crystal structure of a yeast TBP/TATA-box complex. Nature (1993) 7.95

Ageing, fitness and neurocognitive function. Nature (1999) 5.58

An operator at -280 base pairs that is required for repression of araBAD operon promoter: addition of DNA helical turns between the operator and promoter cyclically hinders repression. Proc Natl Acad Sci U S A (1984) 5.42

Each of three "TATA elements" specifies a subset of the transcription initiation sites at the CYC-1 promoter of Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (1985) 4.69

IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol (1997) 4.52

Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med (1991) 4.17

Function of a yeast TATA element-binding protein in a mammalian transcription system. Nature (1988) 3.91

A transcription reinitiation intermediate that is stabilized by activator. Nature (2000) 3.65

Crystal structure of the yeast TFIIA/TBP/DNA complex. Science (1996) 3.45

Mot1, a global repressor of RNA polymerase II transcription, inhibits TBP binding to DNA by an ATP-dependent mechanism. Genes Dev (1994) 3.45

Haemopoietic growth factors in aplastic anaemia: a cautionary note. European Bone Marrow Transplant Working Party for Severe Aplastic Anaemia. Lancet (1994) 3.24

The use of unequal randomisation ratios in clinical trials: a review. Contemp Clin Trials (2005) 2.98

Intermediates in formation and activity of the RNA polymerase II preinitiation complex: holoenzyme recruitment and a postrecruitment role for the TATA box and TFIIB. Genes Dev (1999) 2.94

A yeast and a human CCAAT-binding protein have heterologous subunits that are functionally interchangeable. Cell (1988) 2.84

Variants of the TATA-binding protein can distinguish subsets of RNA polymerase I, II, and III promoters. Cell (1992) 2.76

Yeast HAP2 and HAP3 activators both bind to the CYC1 upstream activation site, UAS2, in an interdependent manner. Cell (1987) 2.73

The tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouse embryo. Genes Dev (1998) 2.72

Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br J Dermatol (2013) 2.70

The role of the TATA-binding protein in the assembly and function of the multisubunit yeast RNA polymerase III transcription factor, TFIIIB. Cell (1992) 2.69

Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med (1996) 2.63

Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med (1993) 2.52

HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med (1996) 2.52

Recruitment of the SWI/SNF chromatin remodeling complex by transcriptional activators. Genes Dev (1999) 2.48

Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J Immunol (1994) 2.41

Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood (2000) 2.40

Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe--impact of cost considerations. Leukemia (2007) 2.39

Task coordination and aging: explorations of executive control processes in the task switching paradigm. Acta Psychol (Amst) (1999) 2.22

An ATP-dependent inhibitor of TBP binding to DNA. Genes Dev (1993) 2.19

A yeast TFIIB-related factor involved in RNA polymerase III transcription. Genes Dev (1992) 2.17

Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol (2000) 2.06

The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta (1995) 2.06

Allogeneic blood stem cell transplantation: considerations for donors. Blood (1997) 2.03

Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplant (2006) 2.01

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant (2009) 2.00

Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia (2004) 1.97

The EBMT activity survey: 1990-2010. Bone Marrow Transplant (2012) 1.96

Health and functional status of long-term survivors of bone marrow transplantation. EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Marrow Transplantation. Ann Intern Med (1997) 1.93

Dominant negative mutations in yeast TFIID define a bipartite DNA-binding region. Cell (1991) 1.91

Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood (1999) 1.88

Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia (2013) 1.88

Upstream repression and CRP stimulation of the Escherichia coli L-arabinose operon. J Mol Biol (1984) 1.84

Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT) Bone Marrow Transplant (1997) 1.83

Cyclosporin A inhibits growth of autocrine tumour cell lines by destabilizing interleukin-3 mRNA. Nature (1994) 1.80

Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? Blood (1992) 1.77

Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol (1995) 1.77

Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation. Lancet (1997) 1.76

Fetal gender and aneuploidy detection using fetal cells in maternal blood: analysis of NIFTY I data. National Institute of Child Health and Development Fetal Cell Isolation Study. Prenat Diagn (2002) 1.74

Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler (2006) 1.70

Transcription of Escherichia coli ara in vitro. The cyclic AMP receptor protein requirement for PBAD induction that depends on the presence and orientation of the araO2 site. J Mol Biol (1986) 1.67

Microvasculopathy in the ocular fundus after bone marrow transplantation. Ann Intern Med (1991) 1.67

The region of phage T4 genes 34, 33 and 59: primary structures and organization on the genome. Nucleic Acids Res (1986) 1.66

Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Ann Intern Med (1999) 1.65

The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant (2011) 1.65

Granulocytic sarcoma after allogeneic bone marrow transplantation: a retrospective European multicenter survey. Acute and Chronic Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (1996) 1.62

Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med (1999) 1.59

Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy--The European Group for Blood and Marrow Transplantation experience. Semin Hematol (2000) 1.59

Fraser syndrome (cryptophthalmos with syndactyly) in the fetus and newborn. Clin Genet (1990) 1.59

Molecular analysis of the SNF2/SWI2 protein family member MOT1, an ATP-driven enzyme that dissociates TATA-binding protein from DNA. Mol Cell Biol (1997) 1.58

Severely reduced presence of tissue macrophages in the basal plate of pre-eclamptic placentae. Placenta (2001) 1.58

Influence of attentional capture on oculomotor control. J Exp Psychol Hum Percept Perform (1999) 1.57

International, collaborative assessment of 146,000 prenatal karyotypes: expected limitations if only chromosome-specific probes and fluorescent in-situ hybridization are used. Hum Reprod (1999) 1.54

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant (2006) 1.53

Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res (2000) 1.53

[S3-Guidelines "Exocrine pancreatic cancer" 2007]. Z Gastroenterol (2007) 1.52

Improvement in outcomes of multifetal pregnancy reduction with increased experience. Am J Obstet Gynecol (2001) 1.50

Isolation of two genes that encode subunits of the yeast transcription factor IIA. Science (1992) 1.49

HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry. Leukemia (2000) 1.49

Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood (2001) 1.48

Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant (2007) 1.47

High stem cell dose will not compensate for T cell depletion in allogeneic non-myeloablative stem cell transplantation. Bone Marrow Transplant (2002) 1.46

Functional hierarchy of AUUUA motifs in mediating rapid interleukin-3 mRNA decay. J Biol Chem (1994) 1.46

In vitro volume measurement by three-dimensional ultrasound: comparison of two different systems. Ultrasound Obstet Gynecol (1998) 1.44

Photodynamic therapy in the canine prostate using motexafin lutetium. Clin Cancer Res (2001) 1.43

In utero diagnosis of congenital varicella zoster virus infection by chorionic villus sampling and polymerase chain reaction. Am J Obstet Gynecol (1991) 1.43

Yeast nuclear extract contains two major forms of RNA polymerase II mediator complexes. J Biol Chem (2001) 1.42

Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood (1998) 1.42

Model for binding of transcription factor TFIIB to the TBP-DNA complex. Nature (1995) 1.41

The smaller than expected first-trimester fetus is at increased risk for chromosome anomalies. Am J Obstet Gynecol (1992) 1.41

[Pre- and postpartum management of hypoplastic left heart syndrome]. Z Geburtshilfe Neonatol (1996) 1.41

Risk evaluation of CVS. Prenat Diagn (1993) 1.40

Lead poisoning from the beauty case: neurologic manifestations in an elderly woman. Neurology (2007) 1.40

[Tau protein. A potential biological indicator for early detection of Alzheimer disease]. Nervenarzt (1998) 1.40

The yeast general transcription factor TFIIA is composed of two polypeptide subunits. J Biol Chem (1991) 1.40

Treatment of acute myelogenous leukemia. An EBMT-EORTC retrospective analysis of chemotherapy versus allogeneic or autologous bone marrow transplantation. Eur J Cancer Clin Oncol (1989) 1.40

Cloning and functional characterization of the gene encoding the TFIIIB90 subunit of RNA polymerase III transcription factor TFIIIB. J Biol Chem (1996) 1.37

Gender, quality of life, and mental disorders in primary care: results from the PRIME-MD 1000 study. Am J Med (1996) 1.37

In vivo regulation of the Escherichia coli araC promoter. J Bacteriol (1983) 1.36

Pancreatic intraepithelial neoplasia revisited and updated. Pancreatology (2008) 1.35

Analysis of the yeast transcription factor TFIIA: distinct functional regions and a polymerase II-specific role in basal and activated transcription. Mol Cell Biol (1995) 1.35

Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients. Eur Respir J (2002) 1.34

Diagnostic yield of bronchoscopy in histologically proven invasive pulmonary aspergillosis. Bone Marrow Transplant (1999) 1.32

Repression of KIAA1199 attenuates Wnt-signalling and decreases the proliferation of colon cancer cells. Br J Cancer (2011) 1.32